[1]Jaeger VK, et al. PLoS One 2016;11:e0163894.
[2]Steen VD et al. Arthritis Rheum 1994;37:1283–9
[3]Walker UA, et al. Ann Rheum Dis 2007;66:754-63.
[4]Hu S, et al. Arthritis Res Ther. 2018 Oct 22;20(1):235.
[5]Fischer A, et al. J Rheumatol. 2018 Feb;45(2):235-241
[6]Bergamasco A, et al. Clin Epidemiol. 2019 Apr 18;11:257-273
[7]Richeldi L, et al. Pooled analysis of data from the TOMORROW and INPULSIS® trials. Resp Med 02/2016. DOI: 10.1016/ j.rmed.2016.02.001.
[8]Richeldi L, du Bois RM, Raghu G, et al; for the INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;380(22):2071-2082
[9]Noth, et al. 于2016年5月13日-18日期间在 ATS 国际大会上介绍(美国加利福尼亚旧金山)
[10]Raghu G, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015 Jul 15;192(2):e3-19.
[11]特发性肺纤维化诊断和治疗中国专家共识[J]. 中华结核和呼吸杂志, 2016, 39(006):427-432.